262 related articles for article (PubMed ID: 30138689)
41. Drug-induced liver injury in the Australian setting.
Sistanizad M; Peterson GM
J Clin Pharm Ther; 2013 Apr; 38(2):115-20. PubMed ID: 23350857
[TBL] [Abstract][Full Text] [Related]
42. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.
Fontana RJ; Hayashi P; Bonkovsky HL; Kleiner DE; Kochhar S; Gu J; Ghabril M
Dig Dis Sci; 2013 Jun; 58(6):1766-75. PubMed ID: 23377559
[TBL] [Abstract][Full Text] [Related]
43. Risk prediction of hepatotoxicity in paracetamol poisoning.
Wong A; Graudins A
Clin Toxicol (Phila); 2017 Sep; 55(8):879-892. PubMed ID: 28447858
[TBL] [Abstract][Full Text] [Related]
44. Serious liver injury induced by Nimesulide: an international collaborative study.
Bessone F; Hernandez N; Mendizabal M; Ridruejo E; Gualano G; Fassio E; Peralta M; Fainboim H; Anders M; Tanno H; Tanno F; Parana R; Medina-Caliz I; Robles-Diaz M; Alvarez-Alvarez I; Niu H; Stephens C; Colombato L; Arrese M; Reggiardo MV; Ono SK; Carrilho F; Lucena MI; Andrade RJ
Arch Toxicol; 2021 Apr; 95(4):1475-1487. PubMed ID: 33759010
[TBL] [Abstract][Full Text] [Related]
45. Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications.
Kaliyaperumal K; Grove JI; Delahay RM; Griffiths WJH; Duckworth A; Aithal GP
J Hepatol; 2018 Oct; 69(4):948-957. PubMed ID: 29792895
[TBL] [Abstract][Full Text] [Related]
46. Hydralazine-induced cholestatic hepatitis.
Hassan A; Hammad R; Cucco R; Niranjan S
Am J Ther; 2009; 16(4):371-3. PubMed ID: 19092641
[TBL] [Abstract][Full Text] [Related]
47. [Terbinafine-induced cholestatic liver injury].
Shiloah E; Horowiz M; Zecler E
Harefuah; 1997 Jul; 133(1-2):11-2, 80-1. PubMed ID: 9332048
[TBL] [Abstract][Full Text] [Related]
48. Utility of Laboratory Test Result Monitoring in Patients Taking Oral Terbinafine or Griseofulvin for Dermatophyte Infections.
Stolmeier DA; Stratman HB; McIntee TJ; Stratman EJ
JAMA Dermatol; 2018 Dec; 154(12):1409-1416. PubMed ID: 30347032
[TBL] [Abstract][Full Text] [Related]
49. [Acute hepatitis associated with terbinafine].
Vivas S; Rodríguez M; Palacio MA; Cadenas F; Lomo J; Rodrigo L
Gastroenterol Hepatol; 1997 Nov; 20(9):456-8. PubMed ID: 9445740
[TBL] [Abstract][Full Text] [Related]
50. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis.
Berson A; Fréneaux E; Larrey D; Lepage V; Douay C; Mallet C; Fromenty B; Benhamou JP; Pessayre D
J Hepatol; 1994 Mar; 20(3):336-42. PubMed ID: 8014443
[TBL] [Abstract][Full Text] [Related]
51. Terbinafine hepatotoxicity: case report and review of the literature.
Fernandes NF; Geller SA; Fong TL
Am J Gastroenterol; 1998 Mar; 93(3):459-60. PubMed ID: 9517658
[TBL] [Abstract][Full Text] [Related]
52. Presentations, Causes and Outcomes of Drug-Induced Liver Injury in Egypt.
Alhaddad O; Elsabaawy M; Abdelsameea E; Abdallah A; Shabaan A; Ehsan N; Elrefaey A; Elsabaawy D; Salama M
Sci Rep; 2020 Mar; 10(1):5124. PubMed ID: 32198411
[TBL] [Abstract][Full Text] [Related]
53. Terbinafine-induced hepatic failure requiring liver transplantation.
Perveze Z; Johnson MW; Rubin RA; Sellers M; Zayas C; Jones JL; Cross R; Thomas K; Butler B; Shrestha R
Liver Transpl; 2007 Jan; 13(1):162-4. PubMed ID: 17192859
[TBL] [Abstract][Full Text] [Related]
54. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study.
Hirata K; Takagi H; Yamamoto M; Matsumoto T; Nishiya T; Mori K; Shimizu S; Masumoto H; Okutani Y
Pharmacogenomics J; 2008 Feb; 8(1):29-33. PubMed ID: 17339877
[TBL] [Abstract][Full Text] [Related]
55. Possible amlodipine-induced hepatotoxicity after stem cell transplant.
Hammerstrom AE
Ann Pharmacother; 2015 Jan; 49(1):135-9. PubMed ID: 25239629
[TBL] [Abstract][Full Text] [Related]
56. Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes.
Quintás G; Martínez-Sena T; Conde I; Pareja Ibars E; Kleinjans J; Castell JV
Arch Toxicol; 2021 Sep; 95(9):3049-3062. PubMed ID: 34274980
[TBL] [Abstract][Full Text] [Related]
57. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B.
Hwang SJ; Wu JC; Lee CN; Yen FS; Lu CL; Lin TP; Lee SD
J Gastroenterol Hepatol; 1997 Jan; 12(1):87-91. PubMed ID: 9076631
[TBL] [Abstract][Full Text] [Related]
58. Flucloxacillin induced delayed cholestatic hepatitis.
Miros M; Kerlin P; Walker N; Harris O
Aust N Z J Med; 1990 Jun; 20(3):251-3. PubMed ID: 2372276
[TBL] [Abstract][Full Text] [Related]
59. Research advances in the association of drug-induced liver injury with polymorphisms in human leukocyte antigen.
Ma Q; Yang W; Wang L; Ma L; Jing Y; Wang J; Liu X
Int Immunopharmacol; 2020 Apr; 81():106037. PubMed ID: 31784402
[TBL] [Abstract][Full Text] [Related]
60. Fenofibrate-induced acute cholestatic hepatitis.
Ho CY; Kuo TH; Chen TS; Tsay SH; Chang FY; Lee SD
J Chin Med Assoc; 2004 May; 67(5):245-7. PubMed ID: 15357112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
